Tislelizumab plus chemoradiotherapy (CRT) versus CRT or chemotherapy (CT) as the neoadjuvant treatment for patients (pts) with locally advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A multicenter, randomized controlled, open-label, phase Ilb study (TERRIFIC)

替雷利珠单抗联合放化疗（CRT）对比CRT或化疗（CT）作为局部进展期胃/胃食管结合部腺癌（GC/GEJC）患者新辅助治疗的多中心、随机对照、开放性IIb期研究（TERRIFIC）

讲者：魏嘉 | 南京鼓楼医院

Real-word treatment patterns and biomarker testing landscape of locally advanced gastric/gastroesophageal junction cancer (LA GC/GEJC) in China (SURPASS study)

中国局部晚期胃癌/胃食管交界处癌症(LAGC/GEJC)的真实世界治疗模式和生物标志物检测格局(SURPASS研究)

讲者：苏丹 | 哈尔滨医科大学附属肿瘤医院

A cohort study of concurrent chemoradiotherapy combined with or without immune checkpoint inhibitor in locally advanced esophageal cancer

一项关于局部晚期食管癌同步放化疗联合或不联合免疫检查点抑制剂的队列研究

讲者：Yiping Lin | 南方医科大学南方医院

Adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (RICE): A prospective, phase 2 trial

阿得贝利单抗联合或不联合诱导化疗序贯同步放化疗治疗不可切除局部晚期食管鳞状细胞癌（RICE）：一项前瞻性2期临床试验

讲者：Shuyi Wu | 中山大学肿瘤防治中心

Healthful Plant-Based Diet Index (hPDI) and risk of upper gastrointestinal cancer: A meta-analysis

健康植物性饮食指数（hPDI）与上消化道癌症风险的荟萃分析

讲者：Chenyu Sun | 梅奥医疗集团

A novel self-controlled electroacupuncture helmet for chemotherapy-induced cognitive impairment: Results from a prospective randomized trial

一款用于化疗所致认知障碍的新型自控电针头盔：来自前瞻性随机试验的结果

讲者：Yongling Gong | 南京市第一医院

Neoadjuvant adebrelimab plus SOX and nab-paclitaxel in resectable locally advanced gastric and gastrosophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase Il trial

新辅助阿得贝利单抗联合SOX方案和白蛋白结合型紫杉醇治疗可切除局部晚期胃及胃食管结合部腺癌：一项多中心、单臂、前瞻性II期临床试验  

讲者：Pin Liang | 大连医科大学附属第一医院

Low-dose radiotherapy followed by chemoimmunotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma: A phase II STIMULATION-01 clinical trial

低剂量放疗序贯化学免疫疗法用于局部晚期食管鳞状细胞癌的新辅助治疗：一项II期STIMULATION-01临床试验

讲者：Yong Yuan | 四川大学华西医院

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma

经匹配调整的间接比较：呋喹替尼与雷莫西尤单抗在晚期胃癌或胃食管结合部腺癌中的疗效对比

讲者：Nan An | 中山大学肿瘤防治中心

A multicenter, randomized phase 2 study evaluating the efficacy and safety of HLX43 (an anti-PD-L1 ADC) in recurrent/metastatic esophageal squamous cell carcinoma

一项评估HLX43（一种抗PD-L1抗体药物偶联物）在复发性/转移性食管鳞状细胞癌中疗效与安全性的多中心、随机化II期临床研究

讲者：Linlin Wang | 山东第一医科大学附属肿瘤医院

A phase 2 study of LBL-007 (anti-LAG-3) plus tislelizumab (anti-PD-1) and chemotherapy as first-line treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma

一项关于LBL-007（抗LAG-3抗体）联合替雷利珠单抗（抗PD-1抗体）及化疗作为不可切除局部晚期/转移性食管鳞状细胞癌患者一线治疗的II期临床研究

讲者：巴一 | 北京协和医学院

Phase Ib/ll study of fruquintinib combined with SOX and toripalimab in advanced metastatic gastric/gastrosophageal junction adenocarcinoma (GC/GEJC)

呋喹替尼联合SOX方案及特瑞普利单抗治疗晚期转移性胃/胃食管结合部腺癌（GC/GEJC）的Ib/II期临床研究    

讲者：孟祥瑞 | 郑州大学第一附属医院

Three-year outcomes and multi-omics biomarker discovery of locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and anti-PD-1 antibody from the phase Il trial NEOCRTEC1901

局部晚期食管鳞状细胞癌新辅助放化疗联合抗PD-1抗体治疗的三年预后及多组学生物标志物发现——来自II期临床试验NEOCRTEC1901的研究结果

讲者：Zihang Mai | 中山大学

Preliminary results of benmelstobart (BEN) combined with concurrent chemoradiotherapy (CRT) versus CRT alone as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC): A multicentre, randomised study

贝莫苏拜单抗（BEN）联合同步放化疗（CRT）与单纯CRT作为食管鳞状细胞癌（ESCC）新辅助治疗的初步结果：一项多中心随机研究

讲者：Han Tang | 湖北省中山医院

Efficacy and safety of disitamab vedotin (RC48) in combination with sintilimab and XELOX for perioperative therapy of G/GEJ cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase Il study

维迪西妥单抗（RC48）联合信迪利单抗及XELOX方案用于HER2过表达型胃/胃食管结合部癌围手术期治疗的疗效与安全性：一项前瞻性单臂II期研究的初步结果

讲者：Ying Liu | 郑州大学附属肿瘤医院

Pembrolizumab in combination with chemotherapy as conversion therapy for esophageal squamous cell carcinoma with cervical lymph node metastasis: A single-center, prospective, single-arm, open-label, real-world study   

帕博利珠单抗联合化疗作为转化疗法治疗伴有颈部淋巴结转移的食管鳞状细胞癌：一项单中心、前瞻性、单臂、开放标签的真实世界研究

讲者：Qi Ding | 中国科学技术大学附属第一医院

Clinical significance of oligometastatic esophageal squamous cell carcinoma: A retrospective cohort study

寡转移性食管鳞状细胞癌的临床意义：一项回顾性队列研究

讲者：Tsung-Che Wu | 台湾大学医学院附属医院新竹分院

Final results of a phase Il study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastrosophageal junction adenocarcinoma (GC/GEJC)

呋喹替尼联合信迪利单抗作为晚期胃癌及胃食管结合部腺癌（GC/GEJC）二线治疗的II期研究最终结果

讲者：Min Jin | 华中科技大学同济医学院

Updated results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Il clinical trial

安罗替尼联合派安普利单抗与白蛋白结合型紫杉醇一线治疗晚期食管鳞状上皮细胞癌(ESCC)的最新研究结果：一项单臂、开放标签的II期临床试验

讲者：Zhiwei Chang | 郑州大学第一附属医院

Proximal gastrectomy versus total gastrectomy in locally advanced upper gastric cancer after neoadjuvant chemotherapy combined with tislelizumab: The preliminary results of a multicenter, prospective, randomized, phase 3 clinical trial

新辅助化学疗法联合替雷利珠单抗治疗后，局部进展期胃上部癌行近端胃切除术与全胃切除术比较：一项多中心、前瞻性、随机、3期临床试验的初步结果

讲者：王桂华 | 华中科技大学同济医学院

A prospective, single-arm phase Il study of trilaciclib combined with immunotherapy and chemotherapy as first-line treatment for metastatic/recurrent esophageal squamous cell carcinoma

一项前瞻性、单臂II期研究：评估曲拉西利联合免疫治疗与化疗作为转移性/复发性食管鳞状细胞癌一线治疗方案的效果

讲者：Yi Wang | 四川省肿瘤医院

Interim analysis of immunomodulatory low-dose radiotherapy plus chemoimmunotherapy as conversion therapy for locally advanced potentially/borderline resectable esophageal squamous cell carcinoma (ROICE trial): A phase Il single-arm study

局部晚期潜在/临界可切除食管鳞状细胞癌转化治疗中免疫调节性低剂量放疗联合化学免疫疗法的中期分析（ROICE试验）：一项II期单臂研究

讲者：任伟 | 南京鼓楼医院